A Case of Asymptomatic, Anicteric Early-stage Intrahepatic Ductal Cholangiocarcinoma.
- Author:
Tae Il PARK
1
;
Myung Hwan KIM
;
Son Mi CHUNG
;
Sang Hyo SHIN
;
I Nae PARK
;
Se Hwan LEE
;
Hyung Suk JI
;
Tae Hyup KIM
;
Sun Jin SYM
;
Sang Soo LEE
;
Dong Wan SEO
;
Sung Koo LEE
;
Young Il MIN
;
Eun Sil YOO
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. mhkim@www.amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Elevated alkaline phosphatase and gamma-GT;
Early-stage bile duct carcinoma;
MRCP;
PTCS
- MeSH:
Adenocarcinoma;
Adenocarcinoma, Papillary;
Alkaline Phosphatase;
Bile Ducts;
Bile Ducts, Intrahepatic;
Biopsy;
Cholangiocarcinoma*;
Cholangiopancreatography, Endoscopic Retrograde;
Constriction, Pathologic;
Dilatation;
Follow-Up Studies;
Humans;
Jaundice;
Liver;
Recurrence;
Cholangiocarcinoma
- From:Korean Journal of Gastrointestinal Endoscopy
2002;25(2):116-120
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Asymptomatic intrahepatic early-stage bile duct carcinoma without jaundice is difficult to diagnose because it does not have any characteristic clinical signs and symptoms. The clinical implication of early-stage intrahepatic ductal cholangiocarcinoma is great, because it allows curative resection and excellent long-term survival. Recently we experienced early-stage intrahepatic cholangiocarcinoma which was incidentally detected by a clue of elevated serum alkaline phosphatase and gamma-GT without jaundice and any symptoms. Abdominal US showed focal intrahepatic bile duct dilatation. ERCP could not demonstrate the lesion, while MRCP revealed the obstructed duct (S6) with proximal dilatation. For evaluation of a focal intrahepatic stricture, PTCS examination and biopsy were done. With the help of MRCP and PTCS, the lesion was diagnosed as papillary adenocarcinoma preoperatively. The patient was underwent right liver lobectomy and confirmed early-stage intrahepatic ductal adenocarcinoma and she is well-being without cancer recurrence for a follow-up period of 1 year.
